[{"id":"13af71f1-2f6f-47c7-a8c9-9d697170772d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04272151","created_at":"2021-03-03T17:53:41.198Z","updated_at":"2024-07-02T16:35:50.362Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT04272151","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCMA CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"eb58053b-f171-4cc3-b6ba-2db156b2fb18","acronym":"","url":"https://clinicaltrials.gov/study/NCT04776330","created_at":"2021-03-03T14:56:37.677Z","updated_at":"2024-07-02T16:35:50.191Z","phase":"Phase 1/2","brief_title":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma","source_id_and_acronym":"NCT04776330","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCMA CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 03/07/2021","start_date":" 03/07/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"}]